Prasol Chemicals delivers 20.82% margin as temporary gains lift performance
Management said Rs 25 cr of pricing impact and Rs 0.92 cr of forex gains supported margins, while West Asia tensions held back export shipments.
Filed 28 Sep 2026, 21:39 IST · after market close · Prasol Chemicals Ltd (PRASOLCHEM)
Key takeaways
- Standalone net profit was Rs 61.02 cr, with operating margin at 20.82% in Q1FY27.
- Management said geopolitical supply-chain pricing effects of Rs 25 cr and forex gains of Rs 0.92 cr lifted margins, with normalisation expected in coming quarters.
- Operating margin was 6.95 percentage points above the 13.87% median for 161 reported Commodities peers.
Price around the results
Q1 margin stood above the Commodities peer median
Prasol Chemicals reported standalone net profit of Rs 61.02 cr on revenue of Rs 433.65 cr in Q1FY27. Operating margin was 20.82%, or 6.95 percentage points above the 13.87% median across 161 Commodities peers that had reported. Other income was Rs 1.71 cr, so the reported profit was primarily operating in nature.
Pricing and forex effects supported margins
Management said average selling price increases linked to geopolitical supply-chain disruption added Rs 25 cr, while foreign-currency fluctuations contributed Rs 0.92 cr. The company said it expects these effects to normalise in coming quarters, making the current margin level important to track for underlying cost and product-mix performance. Management also said secondary and tertiary derivatives grew across both the acetone and phosphorus value chains.
Mahad production improved, but exports faced disruption
Management said Mahad recorded its best-ever quarterly production and improved capacity utilisation in Q1FY27. It also said demand for acetone-based and phosphorus-based products remained healthy, while West Asia-related geopolitical tensions held back export shipments. The company told analysts that it had commercialised 13 products over the past three years, including ZDDP, IPH and PPS.
Expansion plans set the company’s stated growth framework
Management expects FY27 revenue of Rs 1,550-1,650 cr and EBITDA of Rs 240-250 cr, excluding specified price and forex effects. It said Rs 300 cr of capex is planned for existing product lines, with Phase I to be completed in multiple sub-phases over the next two years. The presentation also outlines Phase II spending of Rs 250-300 cr for new R&D products, subject to approvals, with spending expected to begin in H2FY28.
Results were filed after market close
The company filed these standalone results after market close on 28 Sep 2026. The quarter’s market reaction is therefore not covered here.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹434 cr |
| Other income | ₹2 cr |
| Expenses | ₹343 cr |
| Operating profit | ₹90 cr |
| Operating margin (%) | 20.82% |
| Interest | ₹2 cr |
| Depreciation | ₹7 cr |
| Profit before tax | ₹84 cr |
| Tax | ₹23 cr |
| Net profit | ₹61 cr |
| EPS (₹) | ₹10.52 |
Operating margin of 20.82% compares with a Commodities sector median of 13.87% across 161 peers that have reported Q1FY27.
How the stock reacted
| Window | Stock | vs NIFTY |
|---|---|---|
| Results day | +10.00% | +10.28% |
Volume on the results session was 4.06× its 20-day average.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Mahad achieved its best-ever quarterly production and improved capacity utilisation in Q1 FY27.
- Secondary and tertiary derivatives grew in both the acetone and phosphorus value chains during the quarter.
Guidance & outlook
- The company expects FY27 revenue of Rs 1,550–1,650 crores and EBITDA of Rs. 240-250 crores, excluding specified price and forex fluctuations.
- The company expects several of its more than 40 pipeline products to be commercialised in the coming years.
- The company aspires to achieve Rs. 2,800–3,000 crores of revenue over the next five years.
- Phase I expansion revenue at peak utilisation is expected to be Rs. 500–550 crores.
Planned next quarter
- The company expects the quarter’s geopolitical supply-chain and foreign-currency impacts on margins to normalise in coming quarters.
Expansion
- The company plans Rs. 300 crores of capex investments in its existing product line.
- Phase I capex is planned in multiple sub-phases over the next two years.
- Phase II expansion will target new R&D product lines with higher margins and require Rs. 250–300 crores.
- Phase II capex spending is expected to begin in H2FY28, subject to necessary approvals.
New products
- The company has commercialised 13 new products in the last three years.
- The company launched new products including ZDDP, IPH and PPS.
Problems & risks
- Geopolitical tensions from the West Asia conflict held back export shipments.
- The company expects average selling price and foreign-currency impacts linked to geopolitical supply-chain issues to normalise in coming quarters.
- The company identifies external challenges affecting demand and operations despite healthy demand for its products.
What to watch
- Whether operating margin holds above 20.82% as the Rs 25 cr pricing impact and Rs 0.92 cr forex contribution normalise.
- Whether export shipments recover from the disruption management attributed to West Asia tensions.
- Progress against management’s FY27 revenue range of Rs 1,550-1,650 cr and EBITDA range of Rs 240-250 cr.